Introduction
Plasminogen activator inhibitor-i (PAI-1), the primary inhibitor of tissue-type plasminogen activator (t-PA) and urokinase plasminogen activator, is an important regulator of the blood fibrinolytic system. Elevated plasma levels of PAI-1 are associated with thrombosis, and high levels of PAT-i within platelet-rich clots contribute to their resistance to lysis by t-PA. Consequently, strategies aimed at inhibition of PAI-i may prove clinically useful. This study was designed to test the hypothesis that a 14-amino acid peptide, corresponding to the PAI-i reactive center loop (residues 333-346), can rapidly inhibit PAI-i function. PAI-i (0.7 ,uM) was incubated with peptide (55 ,IM) at 37°C. At timed intervals, residual PAT-i activity was determined by addition of reaction mixture samples to t-PA and chromogenic substrate. The T12 of PAI-i activity in the presence of peptide was 4±3 min compared to a control T712 of 98±18 min.
The peptide also inhibited complex formation between PAI-1 and t-PA as demonstrated by SDS-PAGE analysis. However, the capacity of the peptide to inhibit PAI-i bound to vitronectin, a plasma protein that stabilizes PAT-i activity, was markedly attenuated. Finally, the peptide significantly enhanced in vitro lysis of platelet-rich clots and plateletpoor clots containing recombinant PAI-1. These results indicate that a 14-amino acid peptide can rapidly inactivate PAT-i and accelerate fibrinolysis in vitro. These studies also demonstrate that PAT-i function can be directly attenuated in a physiologic setting and suggest a novel approach for augmenting fibrinolysis in vivo. (J. Clin. Invest. 1995. 95:2416-2420.) Key words: fibrinolysis * thrombolysisvitronectin -platelets * serpin Plasminogen activator inhibitor-I (PAI-I),' a serine protease inhibitor that inhibits both tissue-type plasminogen activator (t-PA) and urokinase plasminogen activator, is considered critical in the regulation of vascular fibrinolysis ( 1) . Deficiency of PAI-1 in humans results in an abnormal bleeding tendency (2) , while elevated levels of PAI-I have been associated with myocardial infarction (3) and deep venous thrombosis (4) , suggesting that enhanced PAL-I activity may predispose to vascular disease by limiting intravascular fibrinolysis. Consistent with a critical role of PAI-1 in fibrinolysis, PAI-i-deficient mice generated by targeted disruption of the PAL-I gene demonstrate an enhanced fibrinolytic capacity (5) . In addition to its role in fibrinolysis, PAM-1 has also been implicated in the regulation of several other physiological, plasminogen-dependent processes, including angiogenesis, ovulation, embryogenesis, and cell migration (6) .
PAL-1 is a 50-kD glycoprotein that rapidly inhibits both t-PA and urokinase plasminogen activator by forming 1:I proteaseinhibitor complexes that are enzymatically inactive (1) . PA-1 is present in plasma, vascular smooth cells, and also in endothelial cells and platelets, from which its release can be induced by a variety of agonists, such as thrombin (7, 8) . In addition to reacting with plasminogen activators, PAM-binds to vitronectin (9) and fibrin (10), ligands which appear to play an important role in regulating PAM-1 function. PAT-I is released from endothelial cells in an active conformation but converts spontaneously to an inactive form that can be reactivated in vitro ( II), and possibly in vivo ( 12) . The conversion between active and latent PAM-I conformations is believed to be mediated by a mobile reactive center loop of PAM-1, which, when exposed, results in an active inhibitor, but, when inserted into the major (-sheet A of PAT-i, results in conversion to an inactive, or latent, form (13) .
Given the importance of PAM-1 in fibrinolysis, strategies aimed at its rapid inactivation may be of clinical utility. Consistent with this hypothesis, inhibition of PAM-I with monoclonal antibodies has been shown to enhance fibrinolysis (14) . However, as previously suggested, non-antibody-based strategies of PAM-inhibition are more likely to be clinically applicable ( 15 ) . PAM-1 is a member of a superfamily of structurally related proteins, the serpins (serine protease inhibitors), which includes antithrombin III and a-I-antitrypsin ( 16) . The latter two serpins can each be inhibited by incubation with synthetic 14-amino acid peptides corresponding to their reactive center loop sequences (17, 18) . This process is relatively slow (t12 > 1 h at 37TC) (17, 18) and is thought to occur via insertion of the peptide into ,/-sheet A, interfering with endogenous loop insertion and converting the serpin from an inhibitor to a substrate. The aim of this study is to develop a specific inhibitor of PAI-1 function. As PAI-I is the only serpin known to undergo spontaneous reactive center loop insertion resulting in a latent conformation ( 19) , we hypothesized that a synthetic peptide would insert more rapidly in PAI-1, thus providing an efficient method for inhibiting PAL-i function. We tested the capacity of a tetradecapeptide, based upon residues 333-346 of mature PAI-1 (designated P1-P14) to inhibit PAI-1 activity and to accelerate in vitro clot lysis. The results of these studies indicate that P1-P14 inhibits PAI-1 activity much more efficiently than previously reported for analogous peptides and their corresponding serpins, and they suggest that a peptide-based strategy for inhibition of PAI-1 may prove useful in vivo.
Methods
Materials. The N-acetyl-tetradecapeptide, Ac-Thr-Val-Ala-Ser-Ser-SerThr-Ala-Val-Ile-Val-Ser-Ala-Arg, corresponding to the P1-P14 sequence of PAI-1, was synthesized by the University of Michigan Peptide Synthesis Facility on a multiple peptide synthesizer, (Symphony; Rainin Instrument Co., Inc., Woburn, MA) using the Fmoc (9-fluorenylmethyloxycarbonyl) strategy (18) . A control N-acetyl-tetradecapeptide AcAsp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser was purchased from Bachem Biochemica (Heidelberg, Germany). Lyophilized peptides were dissolved at a concentration of 1 mg/ml in 1 mM HCl containing 1% Tween 80, incubated 15 min at 70'C, and then stored at room temperature. Recombinant PAI-1 (20) and antithrombin III (17) were purified as described previously, and recombinant, single chain t-PA (580,000 IU/mg) was obtained from Genentech, Inc. (South San Francisco, CA). Microcon-30 filtration tubes were from Amicon (Beverly, MA). Human glu-plasminogen, human a-thrombin, and Spectrozyme-tPA were from American Diagnostica, Inc. (Greenwich, CT). Fluorescein-labeled fibrinogen was prepared as previously described (21) , and vitronectin was a gift of D. Mosher.
Inhibitor activity assays. PAI-1 (0.7 OM) was incubated at 37°C with either PI-P14 peptide or control peptide (55 1I.M) in 0.1 M Hepes; 0.1 M NaCl, and 0.1% polyethylene glycol (mol wt 8,000), pH 7.4, (assay buffer). At timed intervals (0-110 min), 5 slI of the PAI-1-peptide mixture was added to 96 well microtiter plates containing 45 IlI of t-PA (0.03 uM in assay buffer), and then incubated for 30 min at 37°C. Spectrozyme t-PA (final concentration of 150 ,M) was added to yield a final reaction vol of 70 ,Il, and 30 min later the absorbance at 405 nm was determined in a microplate reader (THERMO-max; Molecular Devices Corp., Menlo Park, CA). 100% PAI-1 activity was defined as activity observed at time 0, while 0% PAI-1 activity was defined as that observed in the absence of PAI-i. A standard t-PA activity curve, derived from absorbance values of varying concentrations of t-PA incubated in the absence of PAI-1, was used to determine PAI-1 activity. Free peptide was removed by centrifugal ultrafiltration of reaction mixture in a microcon-30 tube (Amicon), according to manufacturer's instructions. 100 gl of the PAI-i -peptide mix was subjected to centrifugation at 8,000 g for 10 min. The residual 10 jA of mix was diluted with an additional 100 ul of assay buffer, and centrifugation was repeated. This process was repeated three times. The inhibition of elastase by a-1-antitrypsin (22) and Factor Xa by antithrombin III were performed as previously described (23) .
SDS-PAGE. SDS-PAGE was performed using a PhastSystem (Pharmacia, Uppssala, Sweden), according to manufacturer's instructions. Gels were stained with Coomassie brilliant blue.
Platelet preparations. Blood samples were collected by peripheral venipuncture from normal subjects into acid-citrate-dextrose anticoagulant (0.8% wt/vol citric acid, 2.2% trisodium citrate, 2.45% dextrose)
at a ratio of 6 vol of blood to I vol of anticoagulant. Donors had not consumed aspirin for at least 7 d before phlebotomy. Washed platelets were prepared by repeated centrifugation as previously described (21) , and then resuspended in Tyrode's buffer ( 137 mM NaCl, 2.68 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 0.36 mM NaH2PO4, 11.9 mM NaHCO3, 5 mM Hepes, 0.1% glucose, and 0.35% BSA, pH 7.35).
In vitro clot lysis assays. Clot lysis assays were performed as previously described (21) . A mixture of glu-plasminogen (0.2 1M), fluorescein-labeled fibrinogen (3 ILM), and PAI-1 (0.7 LM) was prepared.
PI-P14 or control peptide was added to a final concentration of 55 1sM, and clot formation was initiated by the immediate addition of a-thrombin (10 kM). t-PA (20 nM) was added 30 min later, and clot lysis was allowed to occur for 60 min at 370C, after which reaction mixtures were centrifuged (16,000 g for 3 min), and 80 k'l of the supernatant was removed and added to 1.2 ml of 10-mM Tris-HCl and 140-mM NaCl, pH 7.5. The fluorescence of this dilution was measured and percent clot lysis was calculated, as previously described (21) .
In experiments with platelet-rich clots, platelets (2.5 x 108/ml) were added as a source of PAI-1, and t-PA was added to a final concentration of 75 pM immediately after the addition of thrombin. Clot lysis was allowed to proceed for 90 min.
Results
Effect of PJ-P14 peptide on PAI-i activity. PAI-1 spontaneously converts from an active to an inactive, or latent, conformation with a t1/2 of 1-2 h at 370C (24) . Consistent with previous data, we determined the t1/2 of PAI-I to be 98±18 min (mean±SD of three experiments) under the experimental conditions described in Methods. However, addition of PAI-I peptide (55 uM) resulted in a 24-fold shortening of the PAI-1 t1/2 to 4.0±3.0 min. In contrast, a control tetradecapeptide, at the same concentration, did not affect the PAI-i t1/2 (Fig. 1 A) . Control reactions confirmed that neither peptide had any direct effect on t-PA activity. To separate free peptide from PAI-1, the PAI-1-peptide mixture was subjected to centrifugal ultrafiltration with a filter designed to separate molecules < 30 kD. PAI-I remained completely inactivated after this procedure (Fig. 1 B) .
Since vitronectin binds and stabilizes the active conformation of PAI-1, we examined the capacity of the PAI-1 peptide to inactivate vitronectin-bound PAI-i. PAI-i (0.7 MLM) was incubated with vitronectin (1.7 MM) for 30 min at 370C, and then PI-P14 or control peptide (55 MLM) was added, and the PAI-i t1,2 was determined. In the presence of vitronectin, the t1,2 of PAI-1 was prolonged -twofold (98±18-190+12 min), similar to previous reports (25) . However, in contrast to experiments with free PAI-1, the t1,2 of vitronectin-bound PAI-i was shortened only 1.6-fold by PI-P14 peptide (to 120±25 min, Fig. 1 C) .
To determine whether this inhibitory effect was specific for PAI-i, the peptide was tested against other serpins, a-iantitrypsin and antithrombin HI. No peptide inhibition of a-iantitrypsin or antithrombin III was observed, even under conditions where PAI-i was completely inactivated (Fig. 2) .
Effect of PJ-P14 peptide on t-PA-PAI-I complex formation. SDS-PAGE was performed to determine the effect of P1-P14 peptide on t-PA-PAI-I complex formation in the presence and absence of vitronectin. Although control tetradecapeptide did not prevent formation of SDS stable PAI-i-t-PA complexes, no t-PA-PAI-1 complex formation was observed when PAI-i was preincubated for 15 min with PI-P14 peptide. Consistent with the above kinetic data, vitronectin-bound PAI-1 retained the capacity to form complexes with t-PA after treat- or buffer for 15 min at 370C, followed by the addition of corresponding protease and substrate as previously described.
ment with Pl-P14 peptide (Fig. 3) . In contrast to previous studies with other serpins, SDS-PAGE analysis of the products of reaction of t-PA with Pl-P14-treated PAI-1 did not reveal increased amounts of cleaved PAl-1, indicating that the peptide did not convert PAI-1 to a substrate form (26) .
Effect of PJ-PJ4 peptide on in vitro clot lysis. To determine the capacity of the PAM-i peptide to accelerate fibrinolysis, an in vitro clot lysis assay was performed. In the presence of PAI-1, clot lysis at 60 min was accelerated from 28±7% to 90±6% by the addition of Pl-P14 peptide (Fig. 4 A) , while no augmentation of fibrinolysis by Pl-P14 peptide was observed in the absence of PAI-I (Fig. 4 A) . Similarly, the control peptide had no significant effect on clot lysis. Furthermore, the degree of clot lysis was proportional to peptide concentration (Fig. 4 B) .
Since platelets are rich in PAI-1 (27) and platelet-rich thrombi are resistant to t-PA-mediated clot lysis (28) , the effect of peptide on lysis of platelet-rich clots was also assessed. The lysis of platelet-rich clots at 90 min was increased from 8±3% to 41±12% by the addition of Pl-P14 peptide (Fig. 4 C) . 29), the clearance of PAI-I from thrombi and the extravascular compartment is likely to be much longer (7, 30) . The rapidity with which the PI-P14 peptide inactivates PAM-may be of potential clinical importance. PAI-I levels are elevated in young survivors of myocardial infarction (3), and a diurnal variation in PAI-I levels corresponds to the diurnal pattern of myocardial infarction (31) . In addition, PAI-I mRNA levels are elevated in atherosclerotic arteries (32) , and PAM-levels in plasma are positively correlated with the risk of recurrent myocardial infarction (33) . Hence, this peptide approach may provide a practical method to approach acute and possibly chronic suppression of PAM-activity in vivo.
Our results are consistent with previous studies performed with a-l-antitrypsin and antithrombin III (17, 18) . X-ray crystallographic analysis of a-l-antitrypsin indicates that, upon cleavage of the reactive center bond, the PI-P14 loop inserts as a new strand into /3-sheet A (18) . In addition, a synthetic tetradecapeptide consisting of the same stretch of amino acids has been shown to form serpin-peptide complexes with physical properties similar to those of cleaved a-l-antitrypsin (18) , suggesting that the peptide can intercalate into the inhibitor and induce a conformational change that results in serpin inactivation. Studies with antithrombin m produced similar results (17) . The inactivation of PAT-i by P1-P14 peptide is much more rapid than the inactivation of a-i -antitrypsin or antithrombin III by analogous peptides (t1/2 of 4 min vs > 1 h at 37°C), and this loss of activity is still evident after filtration of the PAI--peptide mixture to remove free peptide (Fig. 1 B) . In addition, thermal denaturation studies of peptide-treated PAI-I indicated the melting temperature to be similar to latent PAI-I (data not shown). The rapidity with which PAI-I is inactivated by its PI-P14 peptide may reflect its tendency to assume a latent conformation spontaneously. Unlike antithrombin III and a-1-antitrypsin, however, the substrate form of PAI-1 was not generated after incubation with PI-P14 (Fig. 3) , suggesting an alternative mechanism of PAI-1 inactivation (Francis-Chmura, A. M., et al., unpublished observations). Our data suggest the induction of the latent form of PAM-i by the PI-P14 peptide.
The activities of a-l-antitrypsin, the most abundant serpin in plasma, and antithrombin III, the major regulator of thrombin activity, were not affected by the PI-P14 peptide, demonstrating specificity of the peptide for PAI-I (Fig. 2) . This latter observation is particularly relevant as peptide inhibition of antithrombin III could lead to a procoagulant state in vivo. Though we have shown that the PAI-1 reactive center loop sequence is specific for PAI-i, the capacity of serpins to be inhibited by peptides corresponding to the reactive center loop of foreign serpins has not been previously studied ( 17, 18) . Thus, it remains possible that other serpin reactive center loop peptides could demonstrate inhibitory activity towards PAI-i.
It is of note that the PI-P14 peptide is capable of inactivating PAI-I in the environment of a platelet-rich clot, which contains both fibrin and vitronectin (Fig. 4, A and C) . These ligands probably play important roles in modulating PAM-function in vivo (9, 10) . Vitronectin is present in platelets and plasma and binds PAI-I with high affinity (34, 35) . In addition, vitronectin stabilizes the active conformation of PAI-i, prolonging the tl12 twofold in solution and up to 24 h within the extracellular matrix (25, 30) . The stabilization of PAM-by vitronectin has been hypothesized to result from restriction of PAI-1 3-sheet A, interfering with the reactive center loop insertion that is required for PAI-I conversion to latency (36) . Consistent with this hypothesis, PAI-I bound to vitronectin was highly resistant to peptide inhibition. However, the peptide was capable of accelerating clot lysis despite the presence of vitronectin in platelet-rich clots (Fig. 4 C) . We do not have an explanation for this paradox. It may be that, compared to vitronectin, the peptide reacts more readily with PAI-I in the environment of a clot. PAI-I also binds to fibrin (10), although with lower affinity than vitronectin, and it has been suggested that fibrin may serve to localize PAI-1 to actively forming thrombi (10, 37) . However, under the experimental conditions used in these studies, the PI-PI4 peptide nearly completely inhibited PAI-1 function in the presence of fibrin (Fig. 4 A) .
Since elevated PAM-levels are associated with thrombosis, inhibition of PAI-1 may be a potentially useful therapy in preventing thrombosis. In addition, since platelet-rich thrombi contain markedly elevated levels of PAl-i (38) and PAI-1 contributes to the resistance of platelet-rich clots to lysis with t-PA (21), inhibition of PAI-1 may prove useful in augmenting thrombolysis, as suggested by previous studies with anti-PAI-1 antibodies (14, 37) . The larger volume of distribution of small peptides compared to antibodies might enhance the applicability of PAI-i inactivation, potentially extending its use to in vivo settings. As the plasma concentration of PAI-1 is 8-32 ng/ml (39) , obtaining peptide/PAI-l ratios similar to those in our experiments (i.e., 80-fold molar excess of PI-P14 over PAI-i) could be easily attained in vivo. Furthermore, PI-P14 could provide a powerful model for the rational design of novel, nonprotein inhibitors of PAI-I function.
